Auxilium Pharmaceuticals — Investor Presentation (December 2011)
50 slides from Auxilium Pharmaceuticals's investor presentation, Dec 13, 2011
Slide 1: December 2011
December 2011 (NASDAQ: AUXL) Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks relating to our current plans, potential future events, and what we believe to be the prospects for the Company during this conference call that constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Secur
Slide 3: Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company
Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company Maximize Value of Testim ® and XIAFLEX ® Deliver on Current Pipeline Build Out Pipeline in Specialty Therapeutic Areas
Slide 4: Adrian Adams Has Been Appointed CEO and President of Auxilium
Adrian Adams Has Been Appointed CEO and President of Auxilium 30 years of experience in the pharmaceutical industry, most recently serving as Chairman and CEO of Neurologix, Inc. CEO and President of Inspire Pharmaceuticals, Inc., from 2010 through 2011. CEO and President of Sepracor Inc. from 2007
Slide 5: XIAFLEX and Testim Are Global Product Opportunities
XIAFLEX and Testim Are Global Product Opportunities U.S. Canada EU Japan Open ROW Open Open Territory XIAFLEX Testim
Slide 6: Auxilium Has a Year Net Revenue CAGR of 39.4%
Auxilium Has a 6 Year Net Revenue CAGR of 39.4%
Slide 7: Slide 7
Slide 8: Dupuytren's Contracture Is Debilitating for Patients and Surgery Has Been the Standard of Care
Dupuytren’s Contracture Is Debilitating for Patients and Surgery Has Been the Standard of Care Excessive collagen in fascia of hand Nodules or pits are an early, active presentation Rope-like cords develop in the finger and result in contractures Quality of life and daily activities affected Surgery
Slide 9: We Believe XIAFLEX Is a Paradigm Changing Treatment
We Believe XIAFLEX Is a Paradigm Changing Treatment Simple, non-invasive injection of XIAFLEX Established mechanism of action and selective for specific types of collagen XIAFLEX’s post-approval profile is consistent with clinical trial experience Pre XIAFLEX injection 30 days following XIAFLEX inje
Slide 10: Strategies for Establishing XIAFLEX as the Standard of Care
Strategies for Establishing XIAFLEX as the Standard of Care Leverage excellent clinical efficacy/safety data Generate new data to expand treatable population Facilitate peer to peer dialogue Streamline the reimbursement process Activate patients to seek a non-surgical option
Slide 11: Commercial Changes Designed to Speed Decision Making and Improve XIAFLEX Performance
Commercial Changes Designed to Speed Decision Making and Improve XIAFLEX Performance Eliminated EVP of Sales and Marketing position SVP Sales, and SVP Marketing will report to CEO Changed Professional Advertising Agency and Public Relations Firm Changed Senior Director of Marketing
Slide 12: XIAFLEX Growth Strategy is Tailored to Customer Needs
XIAFLEX Growth Strategy is Tailored to Customer Needs ~ 6,000 target physicians – Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists ~ 100 field based personnel – Sales reps, sales managers, and reimbursement specialists Medical science liaisons – Key opinion lea
Slide 13: We Believe the U.S. Dupuytren's Opportunity Is Significant
We Believe the U.S. Dupuytren’s Opportunity Is Significant 70,000 Surgical 2,3,4 Patients Annually 300,000 Diagnosed Patients Annually 2,3,4 >1 Million Diagnosed Patients 2,4 1. Dupuytren’s Disease – Tubiana, LeClerq, Hurst, Badalamente, Mackin 2. SDI Claims Data Based Projections 3. Medicare Data B
Slide 14: Highlights of Data Released at ASSH Meeting
Highlights of Data Released at ASSH Meeting Post marketing safety experience – No clinically meaningful change in nature of adverse events – Tendon rupture rate per distributed doses significantly lower than in clinical studies Chart review (300 patients): – 63% attain full release following first i
Slide 15: Building on Momentum from ASSH
Building on Momentum from ASSH Introduced Sample program for non-using physicians Introduced Patient co-pay assistance program Initiated Direct Response TV Campaign in 7 Ready Markets Initiated Multi-Cord Phase IV clinical study Obtained CPT Codes Specific for Xiaflex – Effective Jan.1, 2012 Obtaine
Slide 16: Launch Update Through November 2011
Launch Update Through November 2011
Slide 17: Adoption of XIAFLEX is Growing
Adoption of XIAFLEX is Growing ~57% of enrolled sites have ordered XIAFLEX
Slide 18: Growth in Number of Experienced Sites Continues
Growth in Number of Experienced Sites Continues
Slide 19: 2012 Average Medicare Reimbursement Rates for Unique XIAFLEX Procedure Codes
2012 Average Medicare Reimbursement Rates for Unique XIAFLEX Procedure Codes* Expected to Provide Appropriate Value Description Code Amount Office or other outpatient visit, for the evaluation and management of a new patient $102.95 INJECTION, ENZYME (EG, COLLAGENASE), PALMAR FASCIAL CORD (IE, DUPUY
Slide 20: New CPT Codes for XIAFLEX Should Help Streamline Reimbursement in 2012
New CPT Codes for XIAFLEX Should Help Streamline Reimbursement in 2012 We believe the codes should ease the reimbursement processing burden on office staff, speed up the time to payment and increase predictability of payment. Based on experience with the J-code, we believe full utilization of the ne
Slide 21: Testim 1% Testosterone Gel
Testim ® 1% Testosterone Gel Indicated for testosterone replacement therapy in adult males for hypogonadism Launched in U.S. in 2003 and EU in 2006 >8 yrs of use with established safety and efficacy Applied once daily at 5-10mg > ~100M daily doses since launch > clinical studies involving approx. 1,
Slide 22: Hypogonadism Is an Unmet Need and Under-penetrated Market
Hypogonadism Is an Unmet Need and Under-penetrated Market 39% of U.S. males over 45 yrs are hypogonadal > Less than 10% of affected population receives treatment Increasing physician and patient education and awareness should result in increased treatment Mulligan T. et al. Int J. Clin Pract
Slide 23: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data $35 $117 $198 $281 $334 $371 $439 $545 $685 $892 $1,149 $49 $59 $77 $118 $210 $302 $390 $451 $483 $554 $663 $810 $1,041 1,000 1,200 1,400 Gel Patch Oral Injectables ($ in millions) $1,329
Slide 24: Testosterone Replacement Therapy Landscape is Changing
Testosterone Replacement Therapy Landscape is Changing New competition helping expand treated market in 2011 with 17% y/y growth from 3Q10 Maintaining solid market share (21%) due to blunting of competitor launch tactics Testim has expanded covered lives through some wins in managed care
Slide 25: Innevetions for tite
Innevetions for tite
Slide 26: XIAFLEX Represents a Pipeline in a Product
XIAFLEX Represents a Pipeline in a Product - U.S. patent protected through 2028 XIAFLEX XIAFLEX XIAFLEX XIAFLEX XIAFLEX XIAFLEX PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET Dupuytren’s Contracture Peyronie’s Disease Frozen Shoulder Syndrome Canine Lipoma* Cellulite* Human Lip
Slide 27: Peyronie's Disease Is a Devastating Disorder with No Approved Therapies
Peyronie’s disease Is a Devastating Disorder with No Approved Therapies Smith BH. Am J Clin Pathol . 1966;45:670-678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. Scarring phenomenon affecting the tunica albuginea Plaques show excessive collagen deposition Potential Symptoms > Pain with erection
Slide 28: We Believe Peyronie's Disease Is Under-diagnosed and Under-treated
We believe Peyronie’s Disease Is Under- diagnosed and Under-treated Bella A. Peyronie’s Disease J Sex Med 2007;4:1527–1538 Lue TF, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6–23. Mulhall JP, et al. Subjective and objective analysis of the prevalence of Pey
Slide 29: Peyronie's Disease Phase III Development Program
Peyronie’s Disease Phase III Development Program Study Type ~ # Subjects Sites XIAFLEX: Placebo Duration AUX-CC-803 Double-blind, placebo controlled ~ 30 US 5 AUS 2:1 52 Wks AUX-CC-804 Double-blind, placebo controlled ~ 30 US 5 AUS 2:1 52 Wks AUX-CC-802 Open Label 12 US 6 NZ ~ 21 EU N/A 36 Wks AUX-C
Slide 30: Changes to the Phase IIb Trial Design Should Increase the Chance of Success in Phase III
We Believe Changes to the Phase IIb Trial Design Should Increase the Chance of Success in Phase III 4 cycles of therapy in the phase III trial All patients receive modeling All patients must have at least 12 months of disease since diagnosis Mean net improvements in phase IIb penile curvature and bo
Slide 31: Baseline Characteristics in the Phase III Double-blind Trials Are Similar to Phase IIb
Baseline Characteristics in the Phase III Double- blind Trials are Similar to the Phase IIb Clinical Trial Phase III baseline curvature and Peyronie’s disease bother are comparable to the phase IIb baseline. Degree of penile curvature deformity did not correlate with PD bother at baseline (e.g. low
Slide 32: Peyronie's Pivotal Phase III Update
Peyronie’s Pivotal Phase III Update Active dosing phase complete Double-blind patients are now in the 34 week follow-up phase of studies Top line results in Peyronie’s should be available in 2Q12
Slide 33: Collagen Septae Enable Edematous Fibrosclerotic Panniculopathy (EFP)
Collagen Septae Enable Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite Collagen Network
Slide 34: EFP Represents an Unmet Medical Need
EFP Represents an Unmet Medical Need Current non-surgical treatment options have not shown benefit in EFP – OTC pills, creams and lotions. – Unapproved mixtures of enzymes and fat dissolvers – Various devices, including lasers There are currently no FDA approved medical therapies for EFP Surgical ap
Slide 35: Early Pilot Phase I Trial was Encouraging
Early Pilot Phase I Trial was Encouraging Drs. Dagum and Badalamente at SUNY Stony Brook 10 female subjects were treated with a single 0.58 mg dose of collagenase 76% reduction in the physician reported appearance of cellulite and a patient satisfaction score of 1.75 at 6 months – Scale for the pati
Slide 36: Considerable Work Done in Cellulite
Considerable Work Done in Cellulite Pre-IND meeting with FDA to determine a path forward Pre-clinical work done with subcutaneous injections of XIAFLEX at variable doses in a mini-pig study – Lysis of collagen in dermal septae was observed at all doses Completing stability work on new diluent and do
Slide 37: Cellulite – Phase Ib Dose Escalation Study
Cellulite – Phase Ib Dose Escalation Study Expected to begin in 1Q12 Assess the safety and efficacy of XIAFLEX in the treatment of cellulite – Multiple doses in various volumes and concentrations – 10 injection sites over an 8 x 10cm surface area – Seven cohorts followed for 90 days Physician and pa
Slide 38: Collagen Accumulation Can Result in Adhesive Capsulitis
Collagen Accumulation Can Result in Adhesive Capsulitis Normal Shoulder Frozen Shoulder
Slide 39: Adhesive Capsulitis Represents an Unmet Medical Need
Adhesive Capsulitis Represents an Unmet Medical Need Current treatment options have limited results – non-steroidal pain relievers – oral steroids – corticosteroid injections – physical therapy all with limited results. Manipulation of the shoulder under anesthesia or arthroscopic surgery can disrup
Slide 40: Early Pilot Phase II Trial was Encouraging
Early Pilot Phase II Trial was Encouraging Drs. Wang and Badalamente at SUNY Stony Brook – 60 subjects treated with varying doses of collagenase – Following a single injection of collagenase, 8 subjects in the collagenase groups or approximately 16% achieved successful treatment outcomes – In the su
Slide 41: Frozen Shoulder – Phase IIa Dose Escalation Study Underway
Frozen Shoulder – Phase IIa Dose Escalation Study Underway To assess the safety and efficacy of XIAFLEX in the treatment of Frozen Shoulder – Two doses (0.29 and 0.58 mg) given under ultrasound guidance – Approximately 50 subjects across 5 cohorts – Up to three injections 21 days apart – Subjects fo
Slide 42: BTC Will Advance Clinical Studies in Canine and Human Lipomas
BTC Will Advance Clinical Studies in Canine and Human Lipomas Lipomas consist of normal fat encapsulated within a collagen capsule or shell Current treatment options for lipoma include liposuction or surgical excision There are no approved non-surgical therapies We believe XIAFLEX may be beneficial
Slide 43: XIAFLEX – Additional Data and Development Work Ongoing
XIAFLEX – Additional Data and Development Work Ongoing Some small pilot studies were conducted examining the effects of collagenase on lipomas in humans and animals. Investigators noted improvement in lipomas, specifically reduction in their size, following injections of collagenase. BTC is planning
Slide 44: Business Development Efforts Expected to Focus on Building Out Pipeline
Business Development Efforts Expected to Focus on Building Out Pipeline Leverage current infrastructure of Testim and XIAFLEX field forces with additional marketed products Seeking assets in Urology, Orthopedics and Orphan Diseases
Slide 45: Net Revenues Up 24% over 3Q10
Net Revenues Up 24% over 3Q10 Quarter End Quarter End Increase 9/30/2011 9/30/2010 (Decrease) Testim U.S. Revenue $52.9 $47.4 $5.5 Testim Ex – U.S. & Contract Revenue 0.7 0.5 0.2 Total Testim Revenue $53.6 $47.9 $5.7 XIAFLEX U.S. Revenue $10.3 $4.6 $5.7 XIAFLEX Ex – U.S. and Contract Revenue $2.8 1.
Slide 46: 3Q11 Financial Results ($ Millions)
3Q11 Financial Results ($ Millions) (Decr.) 3Q11 3Q10 $ % Total Revenues $ 66.7 $ 53.6 $ 13.1 24% Cost of Goods Sold * $ 13.5 $ 11.6 $ 2.0 17% Gross Profit $ 53.2 $ 42.1 $ 11.1 26% % of Revenues 80% 78% R & D Expense * $ 14.2 $ 14.4 $ (0.3) (2%) SG&A Expense * $ 43.3 $ 40.3 $ 2.9 7% Net Loss $ (4.1)
Slide 47: 2011 Guidance
2011 Guidance Global Testim Revenues $200 - 210 million Xiaflex: US Revenues 45 - 50 million Ex-U.S. / Def Rev* 9 - 11 million Total Xiaflex $54 - 61 million Total Revenues $254 - 271 million R & D Expense $60 - 70 million S G & A Expense $170 - 180 million Net Income (Loss) $(40) - (45) million Sto
Slide 48: We Believe That Auxilium is Well-Positioned for Long-Term Growth
We Believe That Auxilium is Well-Positioned for Long-Term Growth Establish XIAFLEX as the standard of care for Dupuytren’s contracture in the U.S. Maximize Testim in a changing competitive environment Support Pfizer’s launch of XIAPEX for the treatment of Dupuytren’s contracture Complete the Peyroni
Slide 49: Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company
Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company Maximize Value of Testim and XIAFLEX Deliver on Current Pipeline Build Out Pipeline in Specialty Therapeutic Areas
Slide 50: Management Contact
Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 jfickenscher@auxilium.com William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 wsargent@auxilium.com
Auxilium Pharmaceuticals — Investor Presentation (December 2011) on 6ix